infecti
exacerb
chronic
obstruct
pulmonari
diseas
copd
report
occur
viral
bacteri
pathogen
studi
exacerb
associ
isol
nontyp
haemophilu
influenza
sputum
identifi
part
prospect
longitudin
studi
sampl
patient
subject
immunoassay
identifi
new
immun
respons
homolog
isol
nontyp
h
influenza
accur
assess
bacteri
etiolog
patient
also
studi
care
evid
viral
infect
use
viral
cultur
serolog
polymeras
chain
reactionbas
assay
sixteen
exacerb
associ
evid
acut
viral
infect
exacerb
associ
develop
new
serum
igg
homolog
nontyp
h
influenza
overal
evid
infect
respiratori
viru
nontyp
h
influenza
seen
exacerb
associ
viral
infect
immun
respons
nontyp
h
influenza
observ
although
trend
toward
immun
respons
nontyp
h
influenza
absenc
viral
infect
seen
result
show
exacerb
adult
copd
associ
infect
caus
viru
alon
nontyp
h
influenza
alon
viru
nontyp
h
influenza
simultan
infecti
exacerb
chronic
obstruct
pulmonari
diseas
associ
respiratori
virus
nontyp
haemophilu
cours
chronic
obstruct
pulmonari
diseas
copd
character
period
exacerb
diseas
exacerb
associ
substanti
morbid
lead
approxim
million
hospit
admiss
annual
caus
respiratori
failur
requir
mechan
ventil
patient
import
caus
death
copd
exacerb
caus
wide
rang
factor
includ
viral
infect
bacteri
infect
allergi
overload
environment
factor
other
order
develop
success
strategi
better
treat
prevent
exacerb
import
elucid
precis
etiolog
exacerb
unfortun
etiolog
exacerb
determin
certainti
individu
patient
determin
infecti
etiolog
exacerb
particularli
challeng
view
limit
routin
laboratori
test
viral
pathogen
viral
cultur
analysi
clinic
sampl
polymeras
chain
reaction
pcr
serolog
test
sinc
assay
routin
perform
diagnosi
viral
infect
gener
presumpt
clinic
diagnosi
practic
physician
sever
studi
util
assay
identifi
viral
pathogen
establish
viral
infect
associ
proport
exacerb
copd
one
studi
demonstr
respiratori
tract
viral
infect
present
hospit
adult
copd
admit
winter
month
nontyp
haemophilu
common
bacterium
implic
caus
exacerb
copd
goal
present
studi
assess
immun
respons
nontyp
h
isol
sputum
patient
experienc
exacerb
sever
studi
use
approach
howev
one
must
cautiou
interpret
studi
recent
work
establish
immun
respons
nontyp
h
copd
direct
antigen
therefor
order
detect
human
immun
respons
nontyp
h
critic
homolog
infect
strain
use
sourc
antigen
immunoassay
sever
studi
assay
presenc
viral
infect
exacerb
sever
studi
look
care
evid
infect
caus
nontyp
h
studi
use
rigor
method
look
set
patient
present
studi
exacerb
nontyp
h
isol
sputum
cohort
adult
copd
follow
prospect
baylor
colleg
medicin
goal
present
studi
rigor
assess
exacerb
presenc
viral
infect
infect
nontyp
h
evidenc
presenc
organ
sputum
new
immun
respons
homolog
isol
sampl
collect
subject
receiv
care
ben
taub
gener
hospit
harri
counti
hospit
district
enrol
longitudin
studi
chronic
bronchiti
elig
longitudin
studi
subject
chronic
bronchiti
american
thorac
societi
subject
known
asthma
bronchiectasi
malign
immunocompromis
condit
exclud
subject
also
agre
follow
monthli
evalu
seen
sign
symptom
respiratori
ill
develop
studi
sampl
select
subject
exacerb
nontyp
h
isol
sputum
sampl
collect
ill
preand
postexacerb
sera
avail
analysi
ill
interv
cover
pair
sera
exacerb
upper
andor
lower
respiratori
symptom
one
follow
symptom
increas
sputum
product
cough
dyspnea
sputum
specimen
collect
transport
ice
laboratori
within
h
collect
bacteriolog
studi
previous
describ
nasal
wash
throat
swab
specimen
collect
virolog
studi
place
veal
infus
broth
transport
ice
laboratori
within
h
collect
serum
antibodi
studi
collect
visit
time
exacerb
week
later
store
use
serolog
assay
viral
cultur
viru
perform
describ
previous
follow
primari
rhesu
monkey
kidney
cell
biowhittak
walkersvil
md
usa
use
place
madindarbi
canin
kidney
mdck
cell
sampl
two
human
lung
embryon
lung
line
use
sampl
sampl
inocul
onto
human
epidermoid
cell
monkey
kidney
cell
serolog
studi
antibodi
level
respiratori
virus
perform
describ
previous
includ
microneutr
test
b
virus
virus
type
respiratori
syncyti
viru
coronaviru
type
hemagglutin
inhibit
assay
b
virus
enzymelink
immunosorb
assay
elisa
coronaviru
type
revers
transcript
pcr
assay
perform
use
primer
probe
b
virus
picornavirus
coronaviru
type
viru
type
respiratori
syncyti
viru
previous
describ
viru
type
region
f
gene
use
follow
primer
upstream
primer
downstream
primer
viru
type
amplim
use
digoxigeninlabel
oligoprob
isol
nontyp
h
grown
chocol
agar
overnight
co
elisa
strain
grown
shake
incub
midexponenti
phase
optic
densiti
nm
od
brain
heart
infus
broth
contain
hemin
nicotinamid
adenin
dinucleotid
nad
wg
ml
bacteria
reliabl
grow
midexponenti
phase
method
total
grown
chocol
broth
g
proteos
pepton
g
corn
starch
g
potassium
phosphat
dibas
g
potassium
phosphat
monobas
g
sodium
chlorid
mg
hemin
wg
ml
nad
ml
distil
water
isol
nontyp
h
subject
type
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
whole
bacteri
cell
lysat
previous
describ
method
base
larg
mobil
outer
membran
protein
sdsp
age
isol
grown
chocol
agar
overnight
loop
bacteria
suspend
ml
salin
pb
equal
volum
sampl
tri
sd
lmercaptoethanol
glycerol
bromophenol
blue
ad
mixtur
heat
boil
water
bath
min
aliquot
subject
sdsp
age
gel
gel
stain
coomassi
blue
level
igg
human
serum
whole
cell
prepar
homolog
isol
nontyp
h
determin
elisa
well
microtit
plate
immulon
dynatech
coat
overnight
ml
midexponenti
phase
bacteria
suspend
pb
od
well
wash
twice
pb
contain
tween
pbstween
unbound
site
plastic
block
nonfat
dri
milk
pbstween
h
room
temperatur
well
wash
three
time
pbstween
serum
dilut
nonfat
dri
milk
pbstween
wl
ad
well
multipl
dilut
rang
incub
h
well
wash
three
time
pbstween
horseradish
peroxidaseconjug
rabbit
antihuman
f
abp
igg
dako
carpenteria
ca
usa
dilut
goat
serum
ad
well
incub
h
room
temperatur
wash
well
substrat
color
develop
mg
hydrogen
peroxid
per
ml
sodium
acet
adjust
ph
citric
acid
ad
well
incub
min
room
temperatur
reaction
stop
addit
n
h
od
read
pair
sampl
preand
postexacerb
sera
alway
run
togeth
percentag
chang
od
preexacerb
serum
postexacerb
serum
dilut
calcul
use
follow
formula
od
postexacerb
preexacerb
serum
preexacerb
serum
determin
percentag
chang
repres
increas
antibodi
respons
preexacerb
postexacerb
sampl
elisa
perform
pair
serum
sampl
collect
month
apart
adult
copd
follow
monthli
sputum
cultur
grow
nontyp
h
sputum
pair
sera
test
isol
nontyp
h
percentag
chang
od
calcul
describ
exacerb
studi
reason
exclus
studi
includ
failur
obtain
sputum
sampl
ill
n
failur
isol
nontyp
h
sputum
sampl
collect
n
lack
avail
either
preexacerb
convalesc
serum
ill
n
lack
avail
least
one
strain
nontyp
h
ill
sampl
n
ill
select
studi
n
exacerb
occur
subject
nontyp
h
isol
sputum
tabl
show
baselin
clinic
characterist
patient
preexacerb
sera
collect
median
day
rang
day
onset
ill
postexacerb
sera
collect
median
day
rang
day
ill
onset
median
time
ill
onset
clinic
visit
day
rang
day
multipl
coloni
nontyp
h
pick
origin
cultur
plate
grown
individu
possibl
exacerb
two
coloni
rang
coloni
recov
origin
cultur
plate
averag
coloni
per
sampl
recov
isol
total
seven
exacerb
singl
coloni
recov
molecular
type
sdspage
perform
determin
frequenc
singl
multipl
isol
present
sputum
simultan
sampl
multipl
coloni
singl
strain
nontyp
h
three
sputum
sampl
contain
isol
two
band
pattern
sdspage
multipl
band
one
anoth
indic
two
sputum
sampl
two
genet
strain
nontyp
h
simultan
h
elisa
perform
measur
serum
igg
homolog
isol
preexacerb
postexacerb
sera
exacerb
nontyp
h
isol
sputum
pair
preand
postexacerb
sera
alway
test
assay
vari
dilut
set
pair
sampl
test
od
plot
dilut
percentag
chang
pair
preand
postexacerb
sera
measur
dilut
serum
demonstr
linear
relationship
od
dilut
determin
percentag
chang
repres
increas
antibodi
respons
preexacerb
postexacerb
sampl
elisa
perform
pair
serum
sampl
collect
month
apart
adult
copd
grow
nontyp
h
monthli
sputum
sampl
pair
control
sera
demonstr
mean
sd
chang
test
heterolog
isol
nontyp
h
chang
od
repres
upper
limit
interv
control
therefor
chang
od
preto
postexacerb
serum
sampl
regard
chang
three
sputum
sampl
contain
two
isol
nontyp
h
simultan
exacerb
isol
test
individu
elisa
homolog
preand
postexacerb
sera
none
three
patient
statist
igg
respons
either
homolog
sputum
isol
eighteen
respiratori
viral
infect
exacerb
tabl
rhinoviru
cultur
four
subject
type
three
subject
one
subject
serolog
evid
infect
viru
seen
four
subject
type
viru
two
subject
coronaviru
one
subject
rtpcr
assay
three
addit
infect
two
picornaviru
one
type
viru
dual
infect
two
subject
one
rhinoviru
tabl
show
summari
result
virolog
studi
elisa
nontyp
h
exacerb
possibl
combin
observ
includ
evid
simultan
viral
bacteri
infect
absenc
viral
bacteri
infect
evid
individu
three
exacerb
show
evid
viral
infect
also
new
serum
igg
respons
nontyp
h
suggest
coinfect
overal
evid
infect
respiratori
viru
nontyp
h
seen
exacerb
data
analyz
test
hypothesi
evid
viral
infect
absent
immun
respons
nontyp
h
like
immun
respons
nontyp
h
occur
frequent
absenc
viral
infect
reach
statist
p
import
limit
develop
strategi
prevent
exacerb
copd
rel
lack
accur
inform
regard
etiolog
exacerb
individu
patient
special
techniqu
requir
establish
diagnosi
viral
infect
diagnosi
viral
respiratori
tract
infect
clinician
gener
made
clinic
ground
complic
matter
isol
bacteri
pathogen
sputum
adult
copd
exacerb
prove
etiolog
colon
bacteria
occur
absenc
exacerb
therefor
assay
beyond
sputum
cultur
necessari
accur
predict
bacteri
etiolog
present
studi
exacerb
associ
isol
sputum
nontyp
h
part
prospect
studi
patient
studi
care
evid
viral
infect
use
viral
cultur
serolog
pcrbase
assay
addit
sampl
patient
subject
immunoassay
identifi
new
immun
respons
homolog
isol
nontyp
h
accur
assess
bacteri
etiolog
care
evalu
allow
far
accur
assess
etiolog
exacerb
previou
studi
use
similar
method
studi
thu
far
evalu
set
patient
exacerb
copd
viral
bacteri
infect
way
sixteen
exacerb
associ
evid
acut
viral
infect
number
similar
observ
previou
studi
copd
patient
exacerb
includ
whose
sputum
cultur
neg
nontyp
h
frequent
virus
type
picornavirus
pattern
similar
observ
previou
studi
demonstr
new
immun
respons
nontyp
h
isol
sputum
time
exacerb
provid
evid
organ
caus
exacerb
eleven
exacerb
associ
develop
new
serum
igg
homolog
isol
detect
whole
cell
elisa
although
demonstr
new
serum
igg
nontyp
h
provid
support
evid
organ
sputum
etiolog
gold
standard
exist
unequivoc
identifi
organ
caus
individu
exacerb
patient
experi
exacerb
due
bacteria
may
develop
immun
respons
detect
use
whole
cell
elisa
serum
exampl
mucos
immun
respons
occur
independ
system
immun
respons
inde
recent
studi
analysi
system
mucos
antibodi
respons
moraxella
catarrhali
isol
exacerb
copd
reveal
instanc
develop
mucos
iga
respons
absenc
serum
igg
respons
homolog
isol
similarli
cellmedi
immun
respons
antigen
nontyp
h
may
occur
adult
copd
independ
antibodi
respons
therefor
absenc
new
serum
igg
respons
exclud
possibl
exacerb
caus
nontyp
h
possibl
colon
isol
nontyp
h
may
induc
immun
respons
even
absenc
clinic
exacerb
spite
limit
measur
new
serum
igg
nontyp
h
sever
element
design
present
studi
emphas
first
homolog
isol
use
antigen
elisa
assay
seriou
limit
larg
number
publish
studi
immun
respons
nontyp
h
use
laboratori
strain
heterolog
isol
detect
immun
respons
antibodi
respons
follow
infect
nontyp
h
predominantli
direct
epitop
therefor
import
use
homolog
isol
measur
immun
respons
nontyp
h
done
studi
second
adult
human
serum
contain
background
antibodi
mani
antigen
nontyp
h
antibodi
cross
reactiv
antigen
bacteria
bind
surfac
nontyp
h
thu
antibodi
unlik
mediat
protect
immun
respons
present
studi
util
whole
bacteri
cell
elisa
increas
likelihood
antibodi
bind
intact
bacteri
cell
detect
third
import
element
present
studi
avail
sampl
result
prospect
studi
design
serum
prior
onset
symptom
use
preexacerb
serum
sampl
prefer
acut
serum
collect
time
exacerb
sinc
partial
antibodi
respons
may
alreadi
develop
time
patient
evalu
furthermor
assay
preand
postexacerb
serum
allow
us
detect
exclus
new
antibodi
respons
spite
presenc
vari
titer
background
antibodi
final
multipl
strain
nontyp
h
colon
human
respiratori
tract
simultan
present
studi
multipl
coloni
origin
sputum
cultur
plate
subcultur
separ
subject
molecular
type
assess
possibl
multipl
strain
present
three
exacerb
multipl
strain
present
whole
cell
elisa
perform
isol
individu
case
hypothes
patient
show
evid
viral
infect
would
less
like
develop
immun
respons
nontyp
h
patient
lack
evid
viral
infect
trend
direct
observ
data
support
hypothesi
studi
show
exacerb
may
caus
viru
alon
nontyp
h
alon
viru
nontyp
h
simultan
case
evid
simultan
infect
viru
nontyp
h
sever
interpret
possibl
first
exacerb
may
caus
viru
h
colon
induc
immun
respons
second
viral
infect
may
initi
incit
event
exacerb
secondari
infect
nontyp
h
occur
scenario
propos
sever
respiratori
tract
infect
includ
otiti
media
sinus
exacerb
copd
third
viru
may
caus
upper
respiratori
tract
infect
lower
respiratori
tract
symptom
characterist
exacerb
caus
nontyp
h
possibl
draw
conclus
regard
possibl
base
data
present
studi
summari
rigor
method
identifi
evid
viral
infect
appli
sampl
patient
experienc
exacerb
copd
nontyp
h
isol
sputum
total
exacerb
associ
evid
viral
infect
approxim
one
third
associ
develop
serum
igg
respons
homolog
isol
nontyp
h
overal
two
third
exacerb
associ
viral
infect
rise
serum
igg
homolog
isol
nontyp
h
data
indic
exacerb
may
caus
viru
alon
nontyp
h
alon
viru
nontyp
h
simultan
result
highlight
challeng
face
practic
physician
treat
patient
exacerb
copd
emphas
need
better
method
accur
identifi
etiolog
exacerb
copd
